MHRA (Medicines and Healthcare products Regulatory Agency)
The UK regulatory body responsible for ensuring the safety, quality, and efficacy of medicines and medical devices. Following Brexit, the MHRA operates independently from the EMA and maintains its own drug approval process for the UK market.
Technical Context
Post-Brexit, the MHRA operates as an independent sovereign regulator. The Medicines and Healthcare products Regulatory Agency Act 2013 and the Human Medicines Regulations 2012 (as amended) form the legislative framework. The MHRA uses several approval routes: national procedure (UK-only assessment), international recognition procedure (leveraging assessments from trusted regulators including FDA, EMA, Australia, Canada, Japan, Switzerland), and the rolling review pathway (for public health need). The international recognition route can significantly shorten approval timelines for products already assessed by partner agencies. UK marketing authorisations are granted by the MHRA directly (replacing the pre-Brexit role of the European Commission for EU-approved products). The MHRA Yellow Card Scheme remains the UK's pharmacovigilance cornerstone.